MBC taps former cable network online chief to lead tech charge

Share this article:
Medical Broadcasting Company (MBC) has tapped the former online chief of urban marketing giant, Black Entertainment Television, to lead its growing technology team. Navarrow Wright, former chief technology officer for BET.com, signed on as senior vice president of MBC’s technology division in September. Wright told MM&M he plans to merge his mass-market media experience with his knowledge of the latest technologies to help healthcare marketers reach their target consumer and physician audiences. “In expanding areas such as broadband video and mobile, across multiple distribution platforms, consumers and physicians can have greater access to key information to make decisions,” he said. “I look forward to taking that to the next level.” Wright’s resume lists 13-years experience in the design and development of Web applications. While at BET.com, he was able to double the number of the Web site’s registered users and unique visitors. He also served as VP of technology for 360HipHop.com a start-up created by entertainment mogul Russell Simmons. Philadelphia-based MBC, part of consumer interactive agency Digitas, has a well-rounded pharma client roster that includes clients Abbott Laboratories, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi-Aventis, Schering Plough and Wyeth, among others.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...